Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

ConclusionThis study of mavoglurant in OCD was terminated because of the lack of efficacy at interim analysis. The study did not support the use of an antagonist of mGluR5 receptors for OCD treatment.Trial RegistrationThe study was registered with ClinicalTrials.gov: NCT01813019.FundingThis study was sponsored by Novartis Pharma AG, Basel, Switzerland.

http://link.springer.com/10.1007/s12325-016-0468-5

Source: Advances in Therapy - January 1, 2017 Category: Drugs & Pharmacology Source Type: research